NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

NK

NantKwest Inc. Nasdaq Global Select
$35.25
Open: $33.5 High: $36.725 Low: $31.52 Close: $34.99
Range: 2021-02-24 - 2021-02-25
Volume: 2,171,059
Market: Open
Powered by Finage Stock APIDelayed data
NK
NantKwest Inc. 3530 John Hopkins Court San Diego CA, 92121 http://www.nantkwest.com
NantKwest Inc is a biotechnology firm operating mainly in the United States. It undertakes research and discovery of drugs to cure virally-induced cancers, bacterial and fungal diseases. Its pipeline product includes taNK, haNK, and aNK.
  • CEO: Patrick Soon-Shiong
  • Employees: 184
  • Sector: Healthcare
  • Industry: Biotechnology
NK News
Latest news about the NK
  • All Three Independent Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend NantKwest Stockholders Vote "FOR" the Pending Merger With ImmunityBio

    NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. ("ISS"), Glass, Lewis & Co., LLC ("Glass Lewis"), and Egan-Jones Proxy Services ("Egan-Jones") have recommended NantKwest stockholders vote "FOR" the pending merger with ImmunityBio.

    View More →
  • ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors

    ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Clark, retired U.S. Army General, to the company’s board of directors, effective immediately.

    View More →
  • INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - CTB, PBCT, HMSY, NK, SPWH

    Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

    View More →
  • SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Merger Investigation

    WILMINGTON, Del., Feb. 20, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating: NantKwest, Inc. (NASDAQ GS: NK) regarding possible breaches of fiduciary duties and other violations of law related to NantKwest’s agreement to merge with ImmunityBio, Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-nantkwest-inc. Cardtronics plc (NASDAQ GS: CATM) regarding possible breaches of fiduciary duties and other violations of law related to Cardtronics’ agreement to be acquired by affiliates of Apollo Global Management, Inc. and Hudson Executive Capital LP. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-cardtronics-plc. Landcadia Holdings III, Inc. (NASDAQ GS: LCYAU) regarding possible breaches of fiduciary duties and other violations of law related to Landcadia’s agreement to merge with HMAN Group Holdings Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-landcadia-holdings-iii-inc. Crescent Acquisition Corp (NADAQ GS: CRSA) regarding possible breaches of fiduciary duties and other violations of law related to Crescent’s agreement to merge with LiveVox Holdings, Inc. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-crescent-acquisition-corp. You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or info@rl-legal.com. Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide. Attorney advertising. Prior results do not guarantee a similar outcome. CONTACT: Rigrodsky Law, P.A.Seth D. RigrodskyGina M. Serra(888) 969-4242 (Toll Free)(302) 295-5310Fax: (302) 654-7530info@rl-legal.com https://rl-legal.com

    View More →
  • INVESTIGATION ALERT: Halper Sadeh LLP Investigates AEGN, FFG, NK, GWPH; Shareholders Are Encouraged to Contact the Firm

    NEW YORK, NY / ACCESSWIRE / February 20, 2021 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:Aegion Corporation (NASDAQ:AEGN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to affiliates of New Mountain Capital, L. If you are an Aegion shareholder, click here to learn more about your rights and options.

    View More →
  • NK INVESTOR ALERT: Investigation Into Nantkwest

    Boston, MA / ACCESSWIRE / February 17, 2021 / The Thornton Law Firm announces it is investigating potential state or federal claims on behalf of investors in NantKwest, Inc. Investors who currently own shares of NK are encouraged .

    View More →
  • INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, CLGX, SYNC, NK; Shareholders Are Encouraged to Contact the Firm

    NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: MDC Partners Inc. (NASDAQ: MDCA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Stagwell Media LP. Stagwell and its affiliates are expected to hold approximately 79% of the common equity of the combined company after closing. If you are an MDC shareholder, click here to learn more about your rights and options. CoreLogic, Inc. (NYSE: CLGX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to funds managed by Stone Point Capital and Insight Partners for $80.00 per share in cash. If you are a CoreLogic shareholder, click here to learn more about your rights and options. Synacor, Inc. (NASDAQ: SYNC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to an affiliate of Centre Lane Partners, LLC for $2.20 in cash per share. If you are a Synacor shareholder, click here to learn more about your rights and options. NantKwest, Inc. (NASDAQ: NK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with ImmunityBio. Under the terms of the agreement, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned. If you are a NantKwest shareholder, click here to learn more about your rights and options. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com. Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information:Halper Sadeh LLPDaniel Sadeh, Esq.Zachary Halper, Esq.(212) 763-0060sadeh@halpersadeh.comzhalper@halpersadeh.comhttps://www.halpersadeh.com

    View More →
  • ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate

    ImmunityBio, Inc., a privately-held immunotherapy company, today announced the oral presentation of "Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients (Cohort A)" during a session at the Genitourinary Cancers Symposium sponsored by the American Society of Clinical Oncology (ASCO).

    View More →
  • Lifshitz Law Firm, P.C. Announces Investigation of CATM, FFG, NK, and VIE

    NEW YORK, NY / ACCESSWIRE / February 14, 2021 / Lifshitz Law Firm, P.:Cardtronics PLC (NASDAQ:CATM)Lifshitz Law Firm, P.

    View More →
  • INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, FFG, ALXN, NK, HLIX; Shareholders Are Encouraged to Contact the Firm

    Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

    View More →
  • SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger

    Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:

    View More →
  • The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT) Adagene Inc (NASDAQ: ADAG) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO) AnaptysBio Inc (NASDAQ: ANAB) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO) Applied Molecular Transport Inc. (NASDAQ: AMTI) argenx SE – ADR (NASDAQ: ARGX) Atea Pharmaceuticals Inc (NASDAQ: AVIR) AtriCure Inc. (NASDAQ: ATRC) Ayala Pharmaceuticals Inc (NASDAQ: AYLA) Bausch Health Companies Inc (NYSE: BHC) Bolt Biotherapeutics Inc (NASDAQ: BOLT) C4 Therapeutics Inc (NASDAQ: CCCC) Cara Therapeutics Inc (NASDAQ: CARA) Celcuity Inc (NASDAQ: CELC) Checkpoint Therapeutics Inc (NASDAQ: CKPT) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN) DermTech Inc (NASDAQ: DMTK) (announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN) FibroGen Inc (NASDAQ: FGEN) G1 Therapeutics Inc (NASDAQ: GTHX) Genetron Holdings Ltd – ADR (NASDAQ: GTH) GenMark Diagnostics, Inc (NASDAQ: GNMK) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH) Guardion Health Sciences Inc (NASDAQ: GHSI) Horizon Therapeutics PLC (NASDAQ: HZNP) Immunome Inc (NASDAQ: IMNM) Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (announced mid-Phase 2 data for eganelisib in combination of Opdivo for treating advanced urothelial cancer) Intra-Cellular Therapies Inc (NASDAQ: ITCI) Lucira Health Inc (NASDAQ: LHDX) (went public Feb. 5) Medpace Holdings Inc (NASDAQ: MEDP) Merit Medical Systems, Inc. (NASDAQ: MMSI) Merrimack Pharmaceuticals Inc (NASDAQ: MACK) Monopar Therapeutics Inc (NASDAQ: MNPR) (publication of a peer-reviewed study showing the potential utility of MNPR-101 as a uPAR imaging agent to improve surgical outcomes in bladder cancer) NeoGenomics, Inc. (NASDAQ: NEO) Novo Nordisk A/S (NYSE: NVO) Oncternal Therapeutics Inc (NASDAQ: ONCT) Organovo Holdings Inc (NASDAQ: ONVO) Pacific Biosciences of California Inc (NASDAQ: PACB) (reacted to fourth-quarter results) Pacira Biosciences Inc (NASDAQ: PCRX) PAVmed Inc (NASDAQ: PAVM) PLx Pharma Inc (ASDAQ: PLXP) Prothena Corporation PLC (NASDAQ: PRTA) (announced fourth-quarter results) Seelos Therapeutics Inc (NASDAQ: SEEL) Syneos Health Inc (NASDAQ: SYNH) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) (reacted to fourth-quarter results) Vericel Corp (NASDAQ: VCEL) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 12) Galapagos ADR Representing Ord Shs (NASDAQ: GLPG) Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) (went public Wednesday) Stocks In Focus NantKwest Gets FDA Nod For Expanding Early Stage Study Of COVID-19 Vaccine NantKwest Inc (NASDAQ: NK) and ImmunityBio announced the receipt of FDA authorization to expand Phase I testing of a bivalent hAd5 T-cell COVID-19 vaccine. The FDA authorized the expansion of a currently active, multi-cohort trial of the subcutaneous version of the vaccine in order to study the addition of sublingual boosts. The FDA also authorized a second Phase I study that will examine the addition of an oral boost to the subcutaneous prime administration. As a result, the companies will enroll another 105 participants in the U.S. trials of the vaccine candidate, which is unique in targeting both the spike (S) and nucleocapsid (N) proteins of the SARS-CoV-2 virus, the companies said. NantKwest shares were up 14.06% at $29.70 premarket Friday. Pompe Disease Combo Treatment From Amicus Flunks Late-Stage Study Amicus Therapeutics, Inc. (NASDAQ: FOLD) announced topline results from its Phase 3 PROPEL pivotal trial for AT-GAA (cipaglucosidase alfa and miglustat), its investigational two-component therapy for the treatment of late-onset Pompe disease. The primary endpoint, while numerically greater, did not achieve statistical significance for superiority in the AT-GAA arm as compared to the alglucosidase alfa arm. In premarket trading, the stock was down 23.65% to $14.30. Mesoblast Reports Positive Late-Stage Results For Stem Cell Therapy To Treat Chronic Back Pain Mesoblast limited (NASDAQ: MESO) announced positive results from the Phase 3 trial of its allogeneic mesenchymal precursor cell therapy rexlemestrocel-L in 404 enrolled patients with chronic low back pain due to degenerative disc disease refractory to conventional treatments. The results indicate that a single injection of rexlemestrocel-L may provide a safe, durable and effective opioid-sparing therapy for patients with chronic inflammatory back pain due to degenerative disc disease, and the greatest benefits are seen when the drug is administered earlier in the disease process before irreversible fibrosis of the intervertebral disc has occurred, the company said. The stock was down 5.39% premarket to $10.36. Bausch Rallies After Icahn Discloses New Stake Shares of Bausch rose after a 13-D filing by Icahn Capital revealed a 7.8% stake in the company, with the purchase premised on the assumption that the shares are undervalued. The activist investor suggested he plans to discuss with the management and board initiatives to enhance shareholder, including evaluation of strategic options. The stock rallied 6.28% to $30 in after-hours trading. Related Link: The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight Mallinckrodt Says FDA Decision On Burn Treatment Delayed As COVID-19 Holds Up Site Inspection Mallinckrodt PLC (OTC: MNKKQ) said the FDA has informed the company that it is deferring action, pending a site inspection, on the Stratatech biologics license application for StrataGraft, an investigational allogeneic cellularized scaffold product in development for the treatment of adult patients with deep partial-thickness burns. This is due to COVID-19-related travel restrictions, which are delaying a required manufacturing site inspection. Xeris Gets European Regulatory Nod For Glucagon Pen To Treat Low Blood Sugar Levels Xeris Pharmaceuticals Inc (NASDAQ: XERS) announced that the European Commission has approved Ogluo injection for the treatment of severe hypoglycemia in adults, adolescents and children aged 2 years and over with diabetes mellitus. The marketing authorization is valid in all 27 countries in the European Union, plus Iceland, Norway and Liechtenstein. The stock was advancing 27.45% to $8.45 in premarket trading Friday. Alkermes Gains On Insider Buying Alkermes Plc (NASDAQ: ALKS) shares gained after SEC filings revealed two of its directors purchased shares in the company by exercising stock options and restricted stock unit award. The stock was 5% higher premarket at $21.02. Clearpoint Neuro Announces Multiproduct Development Agreement For Neurosurgery Market Clearpoint Neuro Inc (NASDAQ: CLPT) announced a multiproduct joint development and option agreement with Blackrock Microsystems, which specializes in neuroscience, neural engineering and the neural prosthetics space. Blackrock electrodes are used in brain-computer-interfaces to restore function for patients suffering from spinal cord injuries, neurological disorders and amyotrophic lateral sclerosis. The companies expect initial product launches in 2023, starting with the Microelectric Recording platform and to be followed with offerings including smart biopsy needles and other implantable neural electrodes. The stock was adding 10.06% to $28 premarket Friday. Earnings Applied DNA Sciences Inc (NASDAQ: APDN) reported fiscal-year first-quarter revenue of $1.6 million, up from $634,000 in the year-ago period. The net loss per share narrowed from $1.12 to 88 cents. The stock was down 18.62% premarket at $10.23. Aytu Bioscience Inc (NASDAQ: AYTU) reported a strong increase in second-quarter net revenus from $3.175 million in fiscal year 2020 to $15.147 million in fiscal year 2021. The net loss per share widened from 12 cents to 72 cents. The stock was down 4.69% premarket at $8.33. Offerings Corvus Pharmaceuticals Inc (NASDAQ: CRVS) said it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by the company. The stock was down 8.63% premarket at $3.60. Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) announced an increase to the size of the previously announced public offering and purchase on a firm commitment basis of 29.268 million shares of common stock at a price of $1.025 per share. The stock was down 18.66% premarket at $1.09. View more earnings on IBB Protalix Biotherapeutics Inc (NYSE: PLX) priced its previously announced underwritten public offering of 7.619 million shares of its common stock at a price of $4.60 per share. The offering is subject to customary closing conditions and is expected to close on Feb. 17 In premarket trading, the stock was down 16.93% at $4.81. BridgeBio Pharma Inc (NASDAQ: BBIO) announced the launch of a secondary public offering of 3 million shares of its common stock by selling stockholder KKR Genetic Disorder L.P. The company clarified that it is not selling any shares and will not receive any of the proceeds of the offering. The stock was down 3.37% premarket at $65. Phio Pharmaceuticals Corp (NASDAQ: PHIO) said it has entered into definitive agreements with several health care-focused institutional investors for the purchase and sale of 2.247 million shares of its common stock, at a purchase price of $3.42 per share, in a registered direct offering priced at-the-market for gross proceeds of approximately $7.7 million. The stock was moving down 3.6% premarket to $3.48. Infinity Pharmaceuticals Inc. (NASDAQ: INFI) said it has commenced an underwritten public offering of its common stock. All of the shares in the offering will be sold by the company. The stock rose 5.59% premarket to $4.72. Collplant said it has entered into definitive agreements with several health care-focused and other institutional investors for the sale of 2 million ADSs at a purchase price of $17.50 per ADS, in a registered direct offering. Each ADS represents one ordinary share of the company. On The Radar Clinical Readouts 17th Annual WORLDSymposium Presentations Avrobio Inc (NASDAQ: AVRO): uppdated results from a phase 1/2 study of hematopoietic stem cell gene therapy for cystinosis and updated Phase 2 data for AVR-RD-01 in Fabry disease (Friday, Feb. 12) Abeona Therapeutics Inc (NASDAQ: ABEO): updated results from Phase 1/2 study of ABO-101 gene therapy for Mucopolysaccharidosis IIIB and Phase 1/2 study of ABO-102 gene therapy for Mucopolysaccharidosis IIIA (Friday, Feb. 12) Denali Therapeutics Inc (NASDAQ: DNLI): data from Phase 1/2 study of DNL310 in Mucopolysaccharidosis II patients TCT Meeting Presentations Equillium Inc (NASDAQ: EQ): interim data from the Phase 1b/2 EQUATE study of itolizumab in acute graft-versus-host disease Takeda Pharmaceutical Co Ltd (NYSE: TAK): Phase 3 data for TAK-620 in the treatment of transplant recipients with refractory/resistant cytomegalovirus infections Angiogenesis, Exudation, and Degeneration meeting Presentations NGM Biopharmaceuticals Inc (NASDAQ: NGM): data from Phase 1 study of NGM621 in in geographic atrophy Earnings ImmunoGen, Inc. (NASDAQ: IMGN) (before the market open) IPOs Longeveron LLC, a clinical stage biotech developing cellular therapies for specific aging-related and life-threatening conditions, priced its downsized initial public offering of 2.66 million shares at $10, below the estimated price range of $10-$12. The Miami, Florida-based company's shares will begin trading on the Nasdaq under the ticker symbol "LGVN." Talis Biomedical Corporation, which develops molecular diagnostic tests for infectious diseases at the point-of-care, priced its IPO of 13.8 million shares of its common stock at $16 per share, at the upper end of the estimated price range of $14-$16. The gross proceeds to Talis from the offering are expected at about $220.8 million. The shares will begin trading on the Nasdaq under the ticker symbol "TLIS." Decibel Therapeutics priced its IPO of 7.062 million shares of its common stock at a price of $18 per share compared to the estimated price range of $16-$18. All of the shares of common stock are being offered by Decibel. The shares of the clinical-stage biotech developing treatments to restore and improve hearing and balance is expected to begin trading on the Nasdaq under the ticker symbol "DBTX." NexImmune, Inc., a clinical-stage biotech developing immunotherapy to employ the body's own T cells to generate immune response that mimics natural biology, priced its upsized IPO of 6.471 million shares of its common stock at $17 per share, at the high end of the estimated price range of $15-$17. The gross proceeds are expected to be about $110 million. The shares will begin trading on the Nasdaq under the symbol "NEXI." Related Link: Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates See more from BenzingaClick here for options trades from BenzingaThe Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus DebutsThe Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • NantKwest/ImmunityBio's COVID-19 Vaccine Candidate To Be Tested For Oral And Sublingual Route Of Administration

    The FDA has signed off the expansion of Phase 1 testing of a COVID-19 vaccine candidate, developed by NantKwest Inc's (NASDAQ: NK) merger partner, ImmunityBio Inc, to include sublingual boosts (cohort C expansion) to the currently active multi-cohort trial of the subcutaneous version of the vaccine. The agency also authorized a second Phase 1 study that will examine the addition of an oral boost to the subcutaneous prime administration. As a result, the companies will enroll another 105 participants in the U.S. trials. The combination of an oral boost with a subcutaneous prime is based on the findings reported in the NIH/BARDA-sponsored Non-Human Primate study, which showed that when administered with an oral boost, the bivalent vaccine resulted in potent stimulation of spike (S) and nucleocapsid (N)-specific T cells with potent antibody release from memory B cells following viral challenge. Additionally, activation of the full immune system by S and N proteins resulted in complete viral clearance of SARS-CoV-2 in lung and nasal passages following the challenge. Both oral and sublingual trials are anticipated to begin this month. The optimal combination of the route of administration and dose will be determined. The company says that room-temperature stable formulations for oral delivery can potentially solve the cold-chain challenges of distribution and the ability to generate mucosal IgA antibody barriers to the virus in the upper respiratory tract where it first enters the body. In December last year, ImmunityBio announced an all-stock transaction with NantKwest, which would close in the first half of 2021. The combined entity will operate under ImmunityBio moniker focused on oncology and infectious disease. Price Action: NK stock gained 22.9% at $32 during premarket trading on the last check Friday. See more from BenzingaClick here for options trades from BenzingaGenMark Surges On Report Of Potential Takeover Amid Interest From Buyers: BloombergDicerna Starts Dosing With Nedosiran In Primary Hyperoxaluria Early-Stage Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity

    ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have received FDA authorization to expand Phase I testing of a bivalent hAd5 T-cell COVID-19 vaccine. The FDA authorized the expansion of a currently active multi-cohort trial of the subcutaneous version of the vaccine in order to study the addition of sublingual boosts. The FDA also authorized a second Phase I study that will examine the addition of an oral boost to the subcutaneous prime administration. As a result, the companies will enroll another 105 participants in the U.S. trials of their vaccine candidate, which is unique in targeting both the spike (S) and nucleocapsid (N) proteins of the SARS-CoV-2 virus.

    View More →
  • What Kind Of Investors Own Most Of NantKwest, Inc. (NASDAQ:NK)?

    Every investor in NantKwest, Inc. ( NASDAQ:NK ) should be aware of the most powerful shareholder groups. Large...

    View More →
  • INVESTIGATION ALERT: Halper Sadeh LLP Investigates NK, ALXN, CATM, CGIX, MTSC; Shareholders Are Encouraged to Contact the Firm

    Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

    View More →
  • INVESTOR ALERT: Monteverde & Associates Continues to Investigate the Following Merger

    NEW YORK, NY / ACCESSWIRE / February 5, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * NantKwest, Inc. (NASDAQ:NK) relating to its proposed merger with ImmunityBio.

    View More →
  • SHAREHOLDER ALERT: Barr Law Group Investigating NK, PS, JELD, and APLT; Shareholders are Encouraged to Contact the Firm

    SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- National law firm Barr Law Group is investigating the actions of the officers and board of directors of NantKwest, Inc., Pluralsight, Inc., JELD-WEN Holding, Inc., and Applied Therapeutics, Inc. If you are a current owner of shares of any of these stocks, contact leo@barrlaw.com or call (619) 400-4966. NantKwest, Inc. (NASDAQ: NK) Merger Accused of Misleading Investors Barr Law Group is investigating NantKwest, Inc. regarding possible breaches of fiduciary duties and other violations of law related to its merger with ImmunityBio. Under the terms of the agreement, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned. To learn more about this investigation and your rights, visit: http://barrlaw.com/investor-contact. Representation is contingency based, no out of pocket costs. Pluralsight, Inc. (NASDAQ: PS) Merger Accused of Misleading Investors Barr Law Group announces that a class action lawsuit has been filed on behalf of Pluralsight, Inc. investors related to Pluralsight’s agreement to be acquired by Vista Equity Partners. The complaint alleges an unfair price and process. According to the complaint, the price to Vista represents a 9 percent discount to Pluralsight's 52-week high of $22.36 per share, and only a 1 percent premium to the $20 per share price after the company's initial public offering. Just days following the announcement of the merger, several of Pluralsight’s largest shareholders voiced their opposition to the merger. Akaris Global Partners LP, owner of approximately 1% of Pluralsight’s Class A shares, wrote in a letter to Pluralsight’s board that it believes Pluralsight to be worth $30.00 per share and that it intends to vote “AGAINST” the merger. Eminence Capital, a shareholder that holds 4.94% of Pluralsight’s Class A stock, issued a letter to Pluralsight which states that it is “strongly opposed” to the current terms of the merger which provided a “de minimis” premium to stockholders and was “designed to benefit management.” To learn more about this investigation and your rights, visit: http://barrlaw.com/investor-contact. Representation is contingency based, no out of pocket costs. JELD-WEN Holding, Inc. (NYSE: JELD) Shareholder Lawsuit Update Barr Law Group is investigating JELD-WEN Holding, Inc. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders. On October 26, 2020, Judge John A. Gibney, Jr. of the United States District Court for the Eastern District of Virginia issued an order denying the defendants’ motion to dismiss in the pending securities class action, paving the way for litigation to proceed. According to the complaint against Jeld-Wen for alleged violations of the Securities Exchange Act of 1934, defendants misled investors about the company’s competitive advantage and hid that the company was engaged in a price-fixing conspiracy with another door manufacturer to artificially increase or maintain prices of interior molded doors. To learn more about this investigation and your rights, visit: http://barrlaw.com/investor-contact. Representation is contingency based, no out of pocket costs. Applied Therapeutics, Inc. (NASDAQ: APLT) Investigation of Breaches of Fiduciary Duty Barr Law Group is investigating Applied Therapeutics, Inc. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders. To learn more about this investigation and your rights, visit: http://barrlaw.com/investor-contact. Representation is contingency based, no out of pocket costs. Concerned shareholders are encouraged to contact Leo Kandinov to learn more: leo@barrlaw.com (619) 400-4966www.barrlaw.com Barr Law Group is a boutique law firm consisting of highly experienced and specialized litigators who represent investors in securities litigation and corporate governance matters. The firm would be happy to further discuss these matters, and any legal rights or remedies potentially available to you, at no charge. Attorney Advertising. Past results do not guarantee a similar outcome. Contact: Leo Kandinov, Partnerleo@barrlaw.com619-400-4966501 W Broadway Suite 800San Diego, CA 92101www.barrlaw.com

    View More →
  • INVESTIGATION ALERT: Halper Sadeh LLP Investigates PRGX, RP, NK, CGIX; Shareholders Are Encouraged to Contact the Firm

    INVESTIGATION ALERT: Halper Sadeh LLP Investigates PRGX, RP, NK,CGIX; Shareholders Are Encouraged to Contact the FirmNEW YORK, NY / ACCESSWIRE / February 4, 2021 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:PRGX Global, Inc. (NASDAQ: PRGX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Ardian for $7.

    View More →
  • NANTKWEST INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of NantKwest, Inc. - NK

    Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of NantKwest, Inc. (NasdaqGS: NK) with ImmunityBio, Inc. pursuant to which NantKwest shareholders will end up owning just 28% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

    View More →